PMID	Sentence	Disease_mapped	Disease_CUI
23790018	The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that adalimumab was efficacious and well-tolerated for the treatment of hand and / or foot psoriasis through 28Â weeks. 	Psoriasis	C0033860_T047
23790018	In adalimumab-treated patients, greater percentages of Nail Psoriasis Severity Index 50 Responders vs. 	Psoriasis	C0033860_T047
23891453	We present consensus guidelines for the use of acitretin in psoriasis drawn up by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 	Psoriasis	C0033860_T047
24079852	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.	Psoriasis	C0033860_T047
24079852	All eight Psoriasis Symptom Inventory item scores improved significantly among the brodalumab groups by week 12. 	Psoriasis	C0033860_T047
